Coloplast A/ S stock (DK0060448595): Global medical devices leader with steady US growth

Coloplast A/S, a Danish medical device specialist, continues to expand its ostomy and continence care products in the US market. Recent financials show resilient demand amid healthcare sector shifts.

Coloplast A/S maintains its position as a key player in the medical devices sector, particularly appealing to US investors through its strong foothold in chronic care solutions. The company reported steady performance in its latest interim results for the first nine months of fiscal 2025/26, published on February 4, 2026, with organic growth of 5-7% across core segments, according to Coloplast IR as of 02/04/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Coloplast A/S
• Sector/industry: Medical Devices / Chronic Care
• Headquarters/country: Denmark
• Core markets: US, Europe, Emerging Markets
• Key revenue drivers: Ostomy care, Continence care, Interventional Urology, Wound & Skin Care
• Home exchange/listing venue: Nasdaq Copenhagen (COLO B)
• Trading currency: DKK

Coloplast A/S: core business model

Coloplast A/S develops and markets medical devices and services focused on intimate healthcare needs, addressing chronic conditions such as ostomy, continence, and wound care. Founded in 1957, the company has grown into a global leader with products used by millions worldwide. Its business model emphasizes innovation in user-centric design, supported by direct sales to healthcare providers and consumers in over 140 countries.

The core revolves around four business areas: Chronic Care (ostomy and continence), Interventional Urology, and Wound & Skin Care. Coloplast invests heavily in R&D, allocating about 8-10% of revenue annually to develop next-generation products like sensor-based ostomy bags. This approach has driven consistent market share gains, particularly in the US, which accounts for roughly 40% of group revenue as per the annual report for fiscal 2024/25 published November 14, 2025, via Coloplast Annual Report as of 11/14/2025.

Main revenue and product drivers for Coloplast A/S

Ostomy care remains the largest revenue contributor, generating around 45% of sales from pouches, bags, and accessories for patients with stomas following surgery for cancer or inflammatory bowel disease. Continence care, including catheters and collection bags, follows closely at 30%, fueled by aging populations and rising incontinence prevalence. In the US, these segments benefit from Medicare reimbursements and partnerships with distributors like Cardinal Health.

Interventional Urology products, such as percutaneous nephrostomy sets, and Wound & Skin Care lines like biocellulose dressings, make up the balance. Recent launches, including the SenSura Mio Convex barrier introduced in 2025, have boosted uptake. For fiscal 2025/26 Q1-Q3, reported February 4, 2026, organic revenue growth hit 6%, with US growth at 7%, per Coloplast IR as of 02/04/2026. Reported EBIT margin stood at 28%, reflecting pricing power and efficiency gains.

Industry trends and competitive position

The global chronic care market is projected to grow at 5-6% CAGR through 2030, driven by demographics and chronic disease prevalence, according to IQVIA Medtech Outlook as of 01/2026. Coloplast holds leading positions: #1 in ostomy (45% share) and continence (30% share) globally. Competitors like Convatec and Hollister compete aggressively, but Coloplast's innovation edge, with 50+ design awards, sustains its moat.

In the US, Coloplast leverages a direct-to-consumer model alongside B2B channels, aligning with trends toward home-based care post-COVID. Its focus on sustainability, targeting 100% recyclable packaging by 2030, resonates with ESG-conscious investors.

Why Coloplast A/S matters for US investors

US investors track Coloplast A/S for its defensive qualities in healthcare, with stable demand uncorrelated to economic cycles. Listed as an ADR (CLPBY) on OTC markets, it offers exposure to Europe's medtech without direct Copenhagen trading. The US generates nearly half of revenue, exposed to domestic aging trends—65+ population to rise 50% by 2030 per US Census data.

Currency translation benefits from a weaker DKK/USD, boosting reported USD earnings. Dividend yield around 2.5%, paid semi-annually, appeals to income seekers, with payout ratio under 60% supporting growth.

Conclusion

Coloplast A/S demonstrates resilience through its focus on essential chronic care products, with recent results underscoring US market strength and margin discipline. While facing reimbursement pressures and competition, its innovation pipeline and global scale position it well in a growing sector. Investors monitor upcoming Q4 results in August 2026 for guidance updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.